LNZ 600mg Tab 4s

Uses of LNZ 600mg Tab 4s

Linezolid is an anti-biotic and is used in the treatment of various bacterial infections , for example,pneumonia, skin infections, and infections that are resistant to other antibiotics.

Side Effects of LNZ 600mg Tab 4s

Reversible myelosuppression (e.g. leucopenia, thrombocytopenia, anaemia, pancytopenia); headache, fever, convulsions and seizures, rashes, dizziness, nausea and vomiting, metallic taste, insomnia, constipation, diarrhoea, abdominal pain, skin disorder, cough, pharyngitis, upper resp tract infection, visual impairment (e.g. changes in visual acuity or color vision, visual field defect or blurred vision), peripheral and optic neuropathy which progress to loss of vision, lactic acidosis, oral and vaginal candidiasis, superficial teeth and tongue discoloration and abnormal LFT. Potentially Fatal: Serotonin syndrome; transient ischaemic attacks, Stevens-Johnson syndrome.

Drug Interactions

May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol. Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).

Contraindications

Unless facilities for close observation and BP monitoring, avoid use in patients w/ uncontrolled HTN, pheochromocytoma, thyrotoxicosis, carcinoid syndrome, bipolar depression, schizoaffective disorder, acute confusional states. Patients w/ gm-ve bacterial infections. Concomitant use w/ MAOI or w/in 2 wk of discontinuing MAOI; SSRIs, TCAs, selective serotonin- and norepinephrine-reuptake inhibitors (SNRIs), or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone), dopamine, dobutamine, epinephrine, norepinephrine, pseudoephedrine.

Mechanism of Action

Linezolid is a bacteriostatic oxazolidinone which acts by inhibiting ribosomal protein synthesis. It is active against gm+ve bacteria including vancomycin-resistant enterococci and MRSA. It has limited in vitro activity against gm-ve bacteria. Absorption: Rapidly and extensively absorbed after oral admin. Absolute bioavailability: Approx 100%. Time to peak plasma concentration: 1-2 hr but reduced when administered w/ high-fat meal. Distribution: Readily distributed into well-perfused tissues; lungs, fats, bone, skin blister fluids, muscle and into the CSF. Volume of distribution: 40-50 L. Plasma protein binding: Approx 31%. Metabolism: Undergoes hepatic metabolism via oxidation to its 2 inactive metabolites (hydroxyethyl glycine and the aminoethoxyacetic acid metabolite). Excretion: Via urine (approx 30% as parent drug and approx 50% as metabolites); faeces (approx 9% as metabolites). Elimination half-life: Approx 5-7 hr.

Special Precautions

Patients w/ pre-existing myelosuppression, history of seizure, DM, phenylketonuria, mixed (gm+ve and gm-ve) infections. Severe renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor CBC wkly. Monitor visual function in patients on extended therapy (≥3 mth) or in patients w/ new visual symptoms.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.